Carl Icahn has prepared for a proxy fight at Illumina. The billionaire activist plans to nominate three people to the San Diego company’s board, according to a letter Icahn sent to Illumina’s shareholders Monday. (The Wall Street Journal)

Crashing biotech stocks bode ill for the broader market. What does the failure of a major U.S. commercial bank and a weak healthcare sector have in common? Much more than you can imagine. (Seeking Alpha)

Federal health officials have warned parents about what they should know about properly sterilizing breast pump equipment. After it was determined that a baby died of a rare bacterial infection from a contaminated breast pump, the Centers for Disease Control and Prevention is reminding parents and caregivers to properly sanitize the pump parts. (The New York Times)

Jami Rubin is leaving her position as CFO of EQRx, the company disclosed in an SEC filing Monday morning. Rubin informed EQRx of her decision last Wednesday and will leave the biotech at the end of March. (Endpoints News)

Neuralink competitor Science launched a platform to accelerate medical device innovation. The platform, called Science Foundry, allows companies to utilize and build upon Science’s own internal infrastructure by offering access to more than 80 of its tools and services. (CNBC)